, Arthur H. Cohen2, Robert B. Colvin3, J. Charles Jennette4 and Charles E. Alpers5 (1) Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, USA (2) Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center,…
, Arthur H. Cohen2, Robert B. Colvin3, J. Charles Jennette4 and Charles E. Alpers5 (1) Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, USA (2) Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center,…
(1) University of South Australia, Adelaide, Australia Abstract This chapter presents “The pharmacotherapy needs a premium” Game where the Institution that lowers the decision threshold must respond to the…
(1) University of South Australia, Adelaide, Australia Abstract This chapter presents “The pharmaceutical R&D financing” game in which the Institution lowers the decision threshold and must respond to a…
(1) University of South Australia, Adelaide, Australia Abstract If a new drug’s incremental price-effectiveness ratio (IPER) is above the health shadow price, β c , the best alternative strategy…
(1) University of South Australia, Adelaide, Australia Abstract The value of clinical innovation of a new drug is specific to a particular clinical context; the patient group, the clinical…
(1) University of South Australia, Adelaide, Australia Abstract The conventional method of assessing the value of higher prices of new drugs is the ratio of investment in research and…
(1) University of South Australia, Adelaide, Australia Abstract This chapter introduces five concepts central to this book. The opportunity cost of a strategy in an institutional setting is identified…
(1) University of South Australia, Adelaide, Australia Abstract The concluding chapter presents the guide for regulators to playing and winning the new drug reimbursement game. The results from the…
(1) University of South Australia, Adelaide, Australia Abstract The term “innovation” is used in a number of different ways in pharmaceutical regulation processes. In this chapter I address the…
